Journal
FRONTIERS IN BIOSCIENCE-LANDMARK
Volume 14, Issue -, Pages 2285-U41Publisher
BIOSCIENCE RESEARCH INST-BRI
DOI: 10.2741/3379
Keywords
Aromatase; CYP19; Cytochrome P450; CYP; Non-Small Cell Lung Cancer; NSCLC; Estrogen Replacement Therapy; ERT; E. coli; Aromatase Inhibitors; Estrogen Receptor; ER; Progesterone Receptor; PgR; Survival
Categories
Funding
- NIEHS NIH HHS [ES 00267] Funding Source: Medline
- NIGMS NIH HHS [GM37942] Funding Source: Medline
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R37GM037942] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Human aromatase (CYP19) responsible for the conversion of androgens to estrogens is expressed not only in gonads and adrenals but also in many other tissues, including normal lungs and lung cancers. To investigate the involvement of CYP19 in lung cancer development, purified CYP19 protein and antibody are required. In this study, we have developed an efficient expression method of human aromatase in E. coli (> 1000 nmol/L culture). The protein purified from E. coli was used to raise an antibody against the human CYP19 in rabbits. The resulting antibody showed a high titer judged by ELISA, which allowed us to determine the expression of CYP19 in non-small cell lung cancer (NSCLC). Of 78 NSCLC specimens from Japanese patients, 50 (64%) NSCLC aberrantly expressed CYP19. This CYP19 expression in NSCLC was independent of any clinical and pathological parameters as well as the expression of other P450s, except tumor stage. The results suggest that the aromatase inhibitors might be useful for the management of non-small cell lung cancer in postmenopausal women.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available